Impact of sepsis classification and multidrug-resistance status on outcome among patients treated with appropriate therapy

Critical Care Medicine

Volumn 43, Issue 8, 2015, Pages 1580-1586

  Burnham, Jason P ^a   Lane, Michael A ^a   Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Multidrug resistance; Sepsis mortality

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AFRICAN AMERICAN; ANTIBIOTIC THERAPY; APACHE; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE BACTEREMIA; ENTEROBACTERIACEAE INFECTION; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LENGTH OF STAY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEOPLASM; PATIENT TRANSPORT; PRIORITY JOURNAL; RACE; SEPSIS; SEPTIC SHOCK; SOLID ORGAN CANCER; TEACHING HOSPITAL; TREATMENT OUTCOME; AGED; BACTEREMIA; CLASSIFICATION; INTENSIVE CARE UNIT; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; TIME; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84942512504     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001013     Document Type: Article

References (32)

1. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
2. Kollef MH: Broad-spectrum antimicrobials and the treatment of serious bacterial infections: Getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3-13
3. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
4. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155
5. Shorr AF, Micek ST, Welch EC, et al: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 2011; 39:46-51
6. Blot S, Vandewoude K, De Bacquer D, et al: Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: Clinical outcome and length of hospitalization. Clin Infect Dis 2002; 34:1600-1606
7. Figueiredo CS: Impact of antimicrobial resistance on the treatment and outcome of patients with sepsis. Shock 2008; 30:23-29
8. Labelle A, Juang P, Reichley R, et al: The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment. Crit Care Med 2012; 40:2016-2021
9. Paterson DL, Ko WC, Von Gottberg A, et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extendedspectrum beta-lactamases. Clin Infect Dis 2004; 39:31-37
10. Schwaber MJ, Carmeli Y: Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-920
11. Micek ST, Isakow W, Shannon W, et al: Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Pharmacotherapy 2005; 25:26-34
12. Micek ST, Lloyd AE, Ritchie DJ, et al: Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-1311
13. Ha YE, Kang CI, Cha MK, et al: Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum ?-lactamaseproducing Escherichia coli in patients with cancer. Int J Antimicrob Agents 2013; 42:403-409
14. Lin YC, Chen TL, Ju HL, et al: Clinical characteristics and risk factors for attributable mortality in Enterobacter cloacae bacteremia. J Microbiol Immunol Infect 2006; 39:67-72
15. Legrand M, Max A, Peigne V, et al: Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012; 40: 43-49
16. Paul M, Shani V, Muchtar E, et al: Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851-4863
17. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al: Influx of extendedspectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42:925-934
18. Deshpande LM, Jones RN, Fritsche TR, et al: Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12:223-230
19. Guzmán-Blanco M, Labarca JA, Villegas MV, et al; Latin America Working Group on Bacterial Resistance: Extended spectrum ?-lactamase producers among nosocomial Enterobacteriaceae in Latin America. Braz J Infect Dis 2014; 18:421-433
20. Livermore DM: Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012; 27:128-142
21. National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System Report, Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485
22. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
23. Magiorakos AP, Srinivasan A, Carey RB, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281
24. Leligdowicz A, Dodek PM, Norena M, et al; Co-operative Antimicrobial Therapy of Septic Shock Database Research Group: Association between source of infection and hospital mortality in patients who have septic shock. Am J Respir Crit Care Med 2014; 189:1204-1213
25. Schwaber MJ, Navon-Venezia S, Kaye KS, et al: Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamaseproducing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50:1257-1262
26. Zilberberg MD, Shorr AF, Micek ST, et al: Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: A retrospective cohort study. Crit Care 2014; 18:596
27. Micek ST, Heard KM, Gowan M, et al: Identifying critically ill patients at risk for inappropriate antibiotic therapy: A pilot study of a point-ofcare decision support alert. Crit Care Med 2014; 42:1832-1838
28. Awad SS, Rodriguez AH, Chuang YC, et al: A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59:51-61
29. Lucasti C, Hershberger E, Miller B, et al: Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2014; 58:5350-5357
30. Doern CD: Integration of technology into clinical practice. Clin Lab Med 2013; 33:705-729
31. Poulakou G, Bassetti M, Righi E, et al: Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiol 2014; 9:1053-1069
32. Iregui M, Ward S, Sherman G, et al: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-268